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Introduction
Sexual function is an important component of sexual health that determines the general well-
being of a person.1 Female sexual dysfunction (FSD), which is the decrease in sexual desire or 
arousal, or the presence of dyspareunia and difficulty/inability to achieve orgasm, can cause 
personal distress.1 Female sexual dysfunction is a common problem globally, and the factors 
associated with it have been highlighted in the literature and broadly divided into five main 
groups. These include biological factors such as hormonal status that can be influenced by the use 
of hormonal contraception; demographic factors such as age and education levels; psychological 
factors, including mental health conditions, such as anxiety and depression; sociocultural factors 
such as religion and traditional customs; and finally the pathophysiological factors that are 
complications associated with chronic conditions such as diabetes mellitus and rheumatoid 
arthritis. These factors have been illustrated in the biopsychosocial model of FSD. All the above-
described factors are far from having a predictable effect on sexual function and have been shown 
to have variable effects in different studies. They are defined as the association of demographic 
factors such as increasing age, increasing parity and lower levels of education, which have been 
shown to have a significant negative effect on sexual function.2 Other studies draw completely 
Background: Female sexual function (FSD) is a complex phenomenon. It integrates all body 
systems and is influenced by a variety of factors. Contraceptives have shown to have variable 
effects on FSD. In Kenya, the majority of women use hormonal contraception with high 
rates of discontinuation of use, attributed to related side effects such as weight loss and loss 
of libido.
Aim: To determine the prevalence of and the factors affecting FSD among women using 
contraception in our setting.
Setting: The study was carried out at the Aga Khan University Hospital, Nairobi, at various 
clinical sites.
Methods: A cross-sectional study was conducted. Consecutive sampling of women of 
reproductive age using either hormonal or non-hormonal contraception was conducted. Two 
questionnaires were completed after obtaining informed consent. Independent associations 
of factors with the outcome variables were assessed using the chi-square test of association, 
and variables with a p < 0.25 were used in the multivariate analysis. Factors associated with 
FSD were determined using binary logistic regression.
Results: A total of 566 participants were included. The prevalence of FSD among those using 
hormonal and those using non-hormonal contraception was 51.5% and 29.6%, respectively 
(p < 0.0001). We found that the factors associated with FSD were presence of chronic illness and 
use of chronic medication, being self-employed or unemployed, alcohol intake and history of 
miscarriage(s).
Conclusion: There was a high prevalence of and a strong association between hormonal 
contraception and FSD. More studies on this topic in different settings are recommended to 
investigate the effect of each type of hormonal method on FSD.
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opposite conclusions, so no current consensus exists on 
predictability of the effect of most of the above factors.
The current female sexual response model is a circular one, 
which was elaborated by Basson in the year 2000 and has 
evolved from two previous linear models: the first described 
by Masters and Johnson in 1966 and the other that had 
eliminated one of the previously described stages by Kaplan 
et al. in 1979. The non-linear model acknowledges and 
addresses the effect of the other factors, such as relationship 
status and emotional receptivity, on the outcome of sexual 
response and is, therefore, generally more acceptable.3
Contraception is one such factor, the biochemical effects of 
which have a clear association with sexual function, such 
as reduced vaginal lubrication, leading to dyspareunia. The 
current contraceptive prevalence rate in Kenya is 58%, with 
the majority of women using hormonal methods. Significant 
proportions (31%) of the users discontinue use within 1 year 
of starting because of side effects of the contraceptive 
methods.4
Sexuality is a taboo subject in many societies, and women and 
physicians do not routinely discuss effects of contraception 
on sexual health. It was therefore important to examine the 
effect of hormonal contraception on FSD to have contextually 
relevant information for women seeking to be on or already 
on contraception because a high number of women are 
already using hormonal contraception methods.
This study aimed to compare the prevalence of sexual 
dysfunction in women attending the Aga Khan University 
Hospital, Nairobi (AKUHN) clinics using hormonal 
contraception to those using non-hormonal contraception, 
to determine and examine the other factors associated 
with FSD.
Research methods and design
Study design
This was an analytical, cross-sectional survey.
Study setting
The study was carried out at the Aga Khan University 
Hospital, which is a tertiary care referral hospital that 
generally serves a wide variety of individuals with different 
social and demographic characteristics. The clinics identified 
to be used for the study were the family planning clinic, 
family medicine clinic and gynaecology outpatient clinic.
Study population and sampling strategy
The cohort studied were women of reproductive age 
(18–49 years) who were using any form of contraception. To 
be recruited, participants had to be aged 18 years or above to 
give informed consent. Consecutive sampling technique was 
used to recruit participants from the clinics until the required 
sample size was achieved. 
Women attending the above-named clinics, who were in the 
specified age category, were approached by the triage nurse. 
The eligibility of the subjects was confirmed using a set of 
three questions about their age, whether they spoke English 
and if they were using any contraceptive. The eligible women 
who agreed to participate in the study were given two 
questionnaires: the demographic questionnaire and the 
Female Sexual Function Index (FSFI) to be filled in a separate 
private room. The participants were asked to drop them in a 
sealed box at the triage station after they had filled them.
Inclusion criteria 
Women aged between 18 and 49 years who attended the 
AKUHN clinics, and who could read and write in English 
were included in the study. This was mainly because the 
study questionnaire had not been validated in Kiswahili or 
any other local language from our set-up. The participants 
also had to be sexually active and in a heterosexual 
relationship for the past 4 weeks prior to participating in the 
study. The participants had to be using any type of 
contraception, particularly only one type of contraception for 
the past 6 months. 
Exclusion criteria
Women who had a known psychiatric illness and history of 
sexual dysfunction were excluded from the study. Also, 
women who had undergone pelvic floor surgery, had chronic 
pelvic pain syndromes or a history of any gynaecological 
malignancy were excluded, as these conditions are known to 
have a negative influence on sexual function. Women who 
had switched from one type of contraception to another in 
the past 6 months were also excluded as this is the duration 
beyond which, according to the DSM-5, a diagnosis of sexual 
dysfunction can be made from persistence of particular 
symptoms.
Data collection
Sample size calculation 
The formula used for sample size determination was that for 
comparison of proportions between two groups: 
 = − + −
−
×n p p p p
p p
c[ (1 ) (1 )]
( )
1 1 2 2
1 2
2 p.power  [Eqn 1]
where n is the sample size, P1 is the prevalence of sexual 
dysfunction in proportion one and P2 is the prevalence of 
sexual dysfunction in proportion two. The power of the 
study was set at 80%. The value of α was set at 0.05 (95%). 
The Cp.power was 7.9. Using the 2017 study by Oindi et al. 
(an unpublished study conducted at AKUHN), the prevalence 
they obtained from their study was used for calculating 
sample size, where P1 was the prevalence of sexual 
dysfunction in the group of women in the study who were 
using non-hormonal contraception. We aimed to detect at 
least a 10% difference (P1 = 26.9%)
5 in proportion with FSD in 
this group. A 10% difference in prevalence of FSD between 
the two groups was thought to be clinically significant. 
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P2 was the prevalence of sexual dysfunction in the cohort 
of women attending AKUHN clinics using hormonal 
contraception, reported as 36.9%. The calculations using the 
above formula for comparison of proportions gave a sample 
size of 283 women in each arm. This was then multiplied by 
two to get a total sample size of 566 women.
A two-part questionnaire was used to collect the data. The 
first part was about sociodemographic information and 
the second part entailed sexual function in women.
The sociodemographic questionnaire collected information 
on the age of the subject; the age of the partner; parity; race; 
marital status; religion; alcohol intake; smoking status; 
employment status; presence of chronic illnesses, for example, 
hypertension, diabetes mellitus and rheumatoid arthritis; if 
they were currently on any medication for the aforementioned 
conditions; and the type of contraception that was currently 
being used (hormonal or non-hormonal). 
The FSFI questionnaire was used to collect information on the 
outcome variable. This is a 19-item questionnaire that was 
developed as a brief, multidimensional self-report tool to 
assess the important aspects of sexual function in women. It is 
a generally well-accepted tool and has been used in several 
studies across the world. It is easier to administer than most in 
terms of simplicity. It has also been tested for validity and 
inter-rater cross-reliability. The features examined in the 
desire domain include frequency of desiring intercourse, 
level of desire of intercourse, satisfaction and confidence 
with performing intercourse. The arousal domain included 
frequency of successful intercourse and difficulty in getting 
aroused for intercourse. The lubrication domain included 
frequency of attaining and difficulty in maintaining 
lubrication. The pain domain assesses frequency of pain 
during vaginal penetration, frequency following vaginal 
penetration and level of pain during and following vaginal 
penetration. The satisfaction domain mainly assessed factors 
like satisfaction with the amount of closeness with the sexual 
partner, satisfaction with the sexual relationship and, in 
general, satisfaction with one’s sexual life.6
Data analysis
At the end of the day, the questionnaires were checked 
for completion by the triage nurse who then filed the 
questionnaires and stored them in a locked cupboard for 
collection. The data from the forms were entered into a 
Microsoft Excel sheet in a password-protected computer and 
later analysed using SPSS (Statistical Package for the Social 
Sciences) version 22. 
Continuous variables were summarised using means or 
median with their corresponding measures of variability 
(standard deviation [s.d.] or interquartile range [IQR]), while 
categorical data were summarised using frequency counts 
with corresponding percentages. Prevalence of FSD was 
calculated as a proportion of the women with FSD in the 
population of all women interviewed. This was stratified by 
the type of contraceptive (hormonal and non-hormonal) 
used, and the two proportions were compared using two 
sample tests of independent populations.
The FSFI scores were calculated using the responses to the 
questions from each of the domains. All questions had a 
score range of 1 to 5, with two questions for desire domain; 
four questions each for arousal and vaginal lubrication, 
orgasm; and three questions each for pain and sexual 
satisfaction. The total score was calculated by adding the 
scores in a particular domain, and then multiplying it by a 
set coefficient for each domain. The set coefficients were 
0.3 for sexual arousal and vaginal lubrication, 0.6 for desire 
and 0.4 for orgasm, sexual pain and sexual satisfaction. The 
final FSFI score was then calculated by adding all the scores 
for each domain and this ranged between 2 and 36. 
Female sexual dysfunction was measured on a categorical 
binary scale where any woman with a total score of less than 
26.55 is considered to have sexual dysfunction and higher 
scores are indicative of better sexual function (without FSD). 
This tool was developed and validated by Rosen, and its 
reliability was calculated using Cronbach’s alpha for internal 
reliability and multivariate analysis of variance, dysfunction 
diagnosis x FSFI domain with Bonferroni-corrected post hoc 
comparisons to be 0.82.
Independent associations of the explanatory factors with 
the outcome variable were assessed using chi-square test of 
association, and the variables with a p < 0.25 were used in 
the multivariate analysis. Factors associated with FSD were 
determined using binary logistic regression adjusting for 
the influence of the variables on each other or any possible 
confounding factor.
Ethical considerations
The study commenced after ethical approval from the Aga 
Khan University ethics review committee’s consideration. 
Informed consent was obtained prior to recruiting 
participants into the study, and it was made clear that 
participants will be free of coercion, inducement or 
intimidation. Participants in the study did not receive any 
reward. However, declining to participate in the study did 
not interfere with the patients’ intention of attending the 
respective clinic.
Results
A total number of 596 participants were recruited from 
three clinics: gynaecology outpatient clinic, family medicine 
clinic and family planning clinic over the study duration 
of February to April 2018. They submitted completed 
questionnaires of which 30 (5%) were excluded because of 
incomplete data. Data from 566 participants were included 
in the analysis after checking for data completeness and 
confirmation of informed consent and eligibility criteria. The 
mean age of the participants was 32 years with an age range 
of 18–49 years, whereas the mean age of their partners was 
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not much higher at 36 years. Most of the participants were 
married (67%), and the majority had attained tertiary 
education (82%). A large majority (98%) were African. Sixty-
two per cent had salaried employment. Only 13% had a 
chronic illness and 10% were on chronic medication. Most 
(67%) of the women were multiparous and 9% of the 
participants had had at least one miscarriage. Christians 
comprised the majority (97%) and 30% of women used 
alcohol of which 9% used it within recommended limits of 
two units a day and 21% used alcohol in excess of the 
recommended amount for women. A minority (6%) of them 
were active smokers. This has been elaborated in Table 1.
Contraceptive use and female sexual dysfunction
Majority of the participants were using non-hormonal 
contraception (58.5%), mainly male and female condoms 
(21%), natural methods (17%) and the intrauterine device 
(Copper T) (12.%). The rest (41.5%) were using hormonal 
methods, including oral contraceptive pills (13.7%), implants 
(12.4%) and levonorgestrel-releasing intrauterine system 
(6.9%), as shown in Figure 1.
We used the defined cut-off score of 26.55 points to determine 
the participants who had sexual dysfunction. The overall 
prevalence of FSD was 38.7% (219 of the 566 participants) in 
this study population. The hormonal contraceptive users 
had a prevalence rate of 51.5%, while the non-hormonal 
contraceptive users had a prevalence rate of 29.6%, which 
was a significant difference. The prevalence of FSD for 
each of the contraception types is presented in Table 2. The 
prevalence was highest in implant users (63%), followed by 
those on oral contraceptive pill (57%).
We examined the association between the various social and 
demographic factors among all women in the study group 
(Table 3).
The sociodemographic factors found to be significant 
(variables with a p < 0.25) were used in the multivariate 
analysis, described as Model I in Table 4. The factors 
associated were then assessed using binary logistic 
regression adjusting for marital status, level of education 
and age of self, as described in Model II in Table 4. These 
factors were assessed even though they did not meet the 
cut-off significance value, as they are possible confounding 
factors and because other studies had shown their 
significance in association with FSD. There was collinearity 
between alcohol intake and alcohol use; therefore, alcohol 
use was fit in the multivariate model instead of alcohol 
intake. We grouped marital status into single, married and 
others (merged separated, divorced and other), and religion 
was categorised as Christians and others (Islam, no religion, 
other religions) in the regression analysis.
The factor that was found to have a significant association 
with FSD was the use of hormonal contraception, which 
had an adjusted odds ratio of 2.695 (1.869–3.886, p < 0.0001). 
Other factor associations that were found not to be significant 
included self-employment, adjusted odds ratio of 1.362 
(0.883–2.102, p < 0.163); unemployment, adjusted odds 
ratio of 1.247 (0.696–2.234, p < 0.459); alcohol intake 
(excess of recommended limits), adjusted odds ratio of 0.582 
TABLE 1: Sociodemographic characteristics of the study participants.
Social and/or demographic characteristics domain n %
All study participants 566 100.0
Age of subjects (years)
Mean age 32.3 -
Age of partners (years)
Mean age 36 -
Level of education
Primary education 9 1.6
Secondary education 93 16.4
Tertiary education 464 82.0
Relationship status
Single 116 20.5
Married 381 67.3
Separated 9 1.6
Divorced 5 0.9
Other† 55 9.7
Race
African 557 98.0
Asian 6 1.1
Other‡ 3 0.5
Employment status
Salaried employment 355 62.7
Self-employed 137 24.2
Unemployed 74 13.1
Chronic illness
Present 73 12.9
Absent 493 87.1
Use of chronic medication
Present 55 9.7
Absent 511 90.3
Previous pregnancies
Nulliparous 188 33.2
Multiparous 378 66.8
Miscarriages 
Yes 53 9.4
No 513 90.6
Religion
Christian 549 97
Islam 10 1.8
None 6 1.1
Other§ 1 0.2
Alcohol use
Yes 170 30.0
No 396 70.0
Within recommended limits 48 8.5
Excess of recommended limits 122 22.0
Smoking status
Yes 33 5.8
No 533 94.2
Use of hormonal contraception
Yes 235 41.5
No 331 58.5
†,  Others in ‘relationship status’ included ‘engaged’, ‘in a relationship’, ‘dating’, ‘good friends’, 
‘couple’, ‘co-habiting’.
‡, Others in ‘race’ included ‘Arab’, ‘African-American’, ‘mixed-race people’.
§, Other in ‘religion’ included ‘atheist’.
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(0.279–1.212, p < 0.148); having a history of miscarriage(s), 
adjusted odds ratio of 0.613 (0.311–1.211, p < 0.159); having 
a chronic illness, adjusted odds ratio of 0.769 (0.300–1.971, 
p < 0.585); and the use of chronic medication, adjusted odds 
ratio of 0.77 (0.258–2.1, p < 0.59).
The above-named factors showed a trend towards significant 
association with FSD, as described in Model I of Table 4, but 
the study was not powered enough to show this association.
Discussion
The present study showed that the overall prevalence of 
FSD in women in the study group was 38%. In comparison, 
the prevalence of FSD has been reported to be much higher, 
as high as 72.8%, in a Ghanaian prospective cross-sectional 
survey by Amidu et al. and 63% in a Nigerian cross-
sectional study by Fajewonyomi et al. even with the study 
populations having had many similar sociodemographic 
characteristics.7,8
The prevalence of FSD in the women using hormonal 
contraception was 51.5%, compared to 29.6% among those 
using non-hormonal contraception, which was noted to be 
significantly different. On the same note, Wallwiener et al. 
reported that 36.7% of subjects using oral hormonal 
contraceptives and 31.3% of subjects using non-oral 
hormonal contraceptives were found to have FSD as 
compared to 27.4% of subjects using non-hormonal 
contraceptives.9 Although there exists contrary evidence 
that hormonal contraception has shown to increase positive 
indicators of sexual functioning as seen in a prospective 
study conducted by Guida et al.10 in Italy, and in a similar 
study conducted by Higgins et al.11 that showed more 
positive method-related changes in women using hormonal 
contraception, there is not much evidence of the effect of the 
scores of sexual functioning and comparator prevalence 
studies of FSD in the two groups described. In the present 
study, the use of hormonal contraception and the difference 
in the prevalence of FSD in the two groups were noted to be 
statistically significant.10,11
Alcohol intake was not found to have an effect on FSD in 
women who took alcohol within and in excess of the 
recommended limits. This may be attributed the fact that only 
30% of the study sample took alcohol at all. In comparison to 
this, in a study conducted in Ghana by Amidu et al., alcohol 
intake was the only significant risk factor associated with 
FSD. This may be attributed to the physiological effects 
of alcohol on the female genitalia and the psychological 
phenomena of ‘alcohol myopia’ and ‘alcohol expectancy’. 
These are cognitive–physiological theories that are explained 
as a consequence of alcohol’s narrowing of perceptual and 
cognitive functioning. This can affect the expressions and 
emotions of women, and are associated with thoughts of 
pleasure, sexual performance or distress.7
History of miscarriage(s) was also not found to have a 
significant association with FSD in our study. This is contrary 
TABLE 2: Contraceptive use and prevalence of female sexual dysfunction.
Variable n with  
FSD
Total 
eligible
Prevalence 
of FSD (%)
All study participants 219 566 38.7
Participants on hormonal contraceptives 121 235 51.5
Implants 44 70 62.9
Oral contraceptive pill 42 74 56.8
Injectable 16 34 47.1
Hormonal coil 15 39 38.5
Transdermal patches 7 24 29.2
Vaginal rings 1 1 100.0
Participants on non-hormonal contraceptives 98 331 29.6
Male and female condoms 42 119 35.3
Natural methods 42 97 35.3
Non-hormonal coil 19 68 27.9
Tubal ligation 8 31 25.8
Vaginal douching 0 1 0.0
Spermicides 0 1 0.0
FSD, female sexual dysfunction.
FIGURE 1: Frequency of use of contraceptive methods by the study participants.
0.2
0.2
0.2
1.2
4.2
5.5
6.0
6.0
12.0
12.4
13.0
17.1
21.0
0
Male and female condoms
Natural methods
Oral contracepves
Implants
Non-hormonal coil
Hormonal coil
Injecble
Tubal ligaon or vasectomy
Transdermal patches
Lactaonal amenorrhoea method
Vaginal rings
Vaginal douching
spermicides
5 10 15 20 25
Percentage of women who were using the
 type of contracepon
Ty
pe
 o
f c
on
tr
ac
ep

on
% of women
Page 6 of 9 Original Research
http://www.phcfm.org Open Access
to findings of Shreffler et al. in 2011 who discussed how loss of 
pregnancy had a lasting effect of emotions of guilt or distress 
that had strong psychological implications, which could 
eventually lead to a significant effect on sexual function.12
There was no significant association of having a chronic 
illness and the use of chronic medication with FSD in 
our study. This is contrary to most studies that show a 
consistent proportional negative effect of chronic disease on 
sexual function. Many chronic illnesses, such as diabetes, 
HIV and rheumatoid arthritis, exert unwanted effects via 
pathophysiological mechanisms, eventually reducing sexual 
satisfaction scores in the women. The most common chronic 
illness present in our study population was hypertension. 
TABLE 3: Prevalence of female sexual dysfunction across different categories of sociodemographic factors.
Variables Frequency/mean Percent/s.d. FSD p
Absence (n = 347) Present (n = 219)
n % n %
Age of participants (mean) 32.3 7.1 32.5 7.0 32.0 7.4 0.454
Age of partner (mean) 36 7.8 36.2 7.8 35.7 8.0 0.502
Marital status (frequency)
Single 116 20.5 67 57.8 49 42.2 0.296
Married 381 67.3 244 64.0 137 36.0
Separated 9 1.6 4 44.4 5 55.6
Divorced 5 0.9 2 40.0 3 60.0
Other 55 9.7 30 54.6 25 45.4
Level of education 0.924
Primary 9 1.6 6 66.7 3 33.3
Secondary 93 16.4 56 60.2 37 39.8
Tertiary 464 82.0 285 61.4 179 38.6
Race 0.835
African 557 98.4 342 61.4 215 38.6
Asian 6 1.1 3 50.0 3 50.0
Others 3 0.5 2 66.7 1 33.3
Employment status 0.239
Salaried employment 355 62.7 227 63.9 128 36.1
Self-employment 137 24.2 77 56.2 60 43.8
Unemployed 74 13.1 43 58.1 31 41.9
Use of hormonal method < 0.0001
Yes 235 41.5 114 48.5 121 51.5
No 331 58.5 233 70.4 98 29.6
Presence of chronic illness 0.062
Yes 73 12.9 52 71.2 21 28.8
No 493 87.1 295 59.8 198 40.2
Use of chronic medication 0.067
Yes 55 9.7 40 72.7 15 27.3
No 511 90.3 307 60.1 204 39.9
Religion 0.791
Christian 549 97 335 61.0 214 39.0
Muslim 10 1.8 7 70.0 3 30.0
None 6 1.1 4 66.7 2 33.3
Other 1 0.2 1 100.0 0 0.0
Alcohol intake 0.085
Yes 170 30.2 114 66.7 57 33.3
No 395 69.8 233 59.0 162 41.0
Smoking status 0.932
Yes 33 5.8 20 60.6 13 39.4
No 533 94.2 327 61.4 206 38.6
Alcohol use 0.100
Within limits 48 8.5 28 58.3 20 41.7
None 396 70.0 234 59.1 162 40.9
Excessive 122 21.6 85 69.7 37 30.3
Parity 0.818
Nulliparous 188 33.2 114 60.6 74 36.4
Multiparous 378 66.8 233 61.6 145 38.4
Miscarriage 0.054
No 513 90.6 308 60.0 205 40.0
Yes 53 9.4 39 73.6 14 26.4
FSD, female sexual dysfunction.
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As explained above, only a small percentage (12.9%) of 
women in our study population had any chronic illness, had 
a young median age (32 years) and only 9.7% used any 
chronic medication; therefore, our findings are contrary to 
those of Doumas et al. in 2006 that showed a significant 
association of having hypertension with FSD in a larger 
study of sexually active, hypertensive women.13
The present study also showed that being self-employed or 
unemployed did not have a significant effect on sexual 
dysfunction. This was in comparison to the association of 
employment status and FSD that has been shown in many 
different studies conducted in different parts of the world. 
This is attributed to the assumption that women who are 
more financially stable are likely to have higher levels of 
confidence and self-esteem, contributing to higher sexual 
satisfaction scores than unemployed women. Employed 
women also tend to have better interpersonal skills that are 
associated with better desire and more willingness to have 
sexual activity.14
There was no significant effect of smoking on FSD in our 
study population, which is contrary to findings reported in 
other studies that have shown stronger associations. This is 
TABLE 4: Parameter estimates of the factors associated with female sexual dysfunction.
Variables Model I Model II
OR 95% CI p OR 95% CI p
Marital status
Single - - - - - -
Married 0.768 0.503–1.173 0.221 0.554 0.333–0.922 0.023
Other† 1.253 0.688–2.282 0.460 1.235 0.658–2.320 0.511
Level of education
Primary - - - - - -
Secondary 1.321 0.311–5.615 0.706 0.941 0.199–4.442 0.938
Tertiary 1.256 0.310–5.086 0.749 1.086 0.241–4.895 0.914
Race
African - - - - - -
Asian 1.591 0.318–7.952 0.572 - - -
Others 0.795 0.072–8.824 0.852 - - -
Employment status
Salaried employment - - - - - -
Self-employment 1.382 0.925–2.063 0.114 1.362 0.883–2.102 0.163
Unemployed 1.278 0.768–2.129 0.345 1.247 0.696–2.234 0.459
Use of hormonal method
Yes 2.524 1.782–3.574 < 0.0001 2.695 1.869–3.886 < 0.0001
No - - - - - -
Presence of chronic illness
Yes 0.602 0.351–1.030 0.064 0.769 0.300–1.971 0.585
No - - - - - -
Use of chronic medication
Yes 0.564 0.304–1.048 0.07 0.77 0.258–2.296 0.639
No - - - - - -
Religion
Christian - - - - - -
Other‡ 0.652 0.226–1.877 0.428 - - -
Smoking status
Yes 1.032 0.52–2.119 0.932 - - -
No - - - - - -
Age of participants 0.991 0.968–1.015 0.454 1.01 0.979–1.040 0.561
Age of partner 0.993 0.971–1.014 0.502 - - -
Alcohol use
Within limits - - - - - -
None 0.969 0.528–1.780 0.92 0.977 0.510–1.871 0.943
Excessive 0.609 0.305–1.217 0.16 0.582 0.279–1.212 0.148
Parity
Nulliparous - - - - - -
Multiparous 0.959 0.670–1.372 0.818 - - -
Miscarriage
No - - - - - -
Yes 0.539 0.286–1.018 0.057 0.613 0.311–1.211 0.159
FSD, female sexual dysfunction; CI, confidence interval; OR, odds ratio.
†, Others in ‘relationship status’ included ‘engaged’, ‘in a relationship’, ‘dating’, ‘good friends’, ‘couple’, ‘co-habiting’.
‡, Others in religion’ included ‘atheist’.
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related to mechanisms of the negative effects of nicotine on 
the vascular system, reducing genital blood flow by inhibiting 
vasoactive substances such as endothelial relaxing factor and 
nitric oxide. This association was not seen in the present 
study, which is most likely because of the small number 
(5.8%) of active smokers in the population compared to larger 
populations of smokers in Europe and the United States.
The study participants were noted to be a generally young 
population with small age gaps with their partners. A large 
number were non-smokers and did not take alcohol, and was 
reflected as very few of them having chronic illnesses and 
fewer of them using any chronic medications. Majority of 
them shared characteristics such as being married, having a 
tertiary education and being employed. An expected finding 
was that most women belonged to the African race, were 
Christians and had had more than one pregnancy.14
It was noted in the present study that more participants 
were using non-hormonal methods of contraception than 
hormonal methods, mainly male and female condoms, and 
natural methods. In the group of hormonal contraception 
users, most were using oral contraceptives and implants. 
This is contrary to the report of the Kenya Demographic and 
Health Survey, which stated a higher prevalence of hormonal 
contraception with majority using injectable methods.4
Increasing age of participants and higher ages of their 
partners have shown to have a significant negative effect on 
sexual dysfunction as seen in other studies, but this did not 
reflect in our findings; however, it could be largely because of 
a younger mean age of participants in the present study and 
smaller age gaps with their partners as seen in the present 
study population.14
The present study did not find a significant association 
between the level of education and FSD. This association has 
not been clearly defined in the literature as well as with some 
studies showing an inverse effect of the years of education 
and prevalence of FSD such as the cross-sectional study 
conducted in Nigeria by Fajewonyomi et al. Other larger 
studies still report a proportionate effect on FSD. The 
association may not have come out very clear in the present 
study population as majority of the participants had attained 
tertiary level of education – there were very few with lower 
levels of education.14
The limitations of this study were that the findings may not 
be generalisable to the entire population of Kenya as it was 
conducted in a tertiary hospital, in the private health care 
clinical setting, with majority of the participants having 
high education levels, more financial security and health 
insurance, and higher employment levels. This also limited 
the ability of the study to elaborate on other associations 
that were close to significant in the study sample such as 
employment, education levels and religion. Also, stratification 
of the different types of FSD was not done as part of the data 
analysis in this study.
Further research to build on womens’ sexual health and 
sexual function should be conducted in more centres 
including rural settings in Kenya after adequate translation 
and validation of FSFI questionnaire to Kiswahili and in 
populations where some of the expected associations can be 
better evaluated and to build on this knowledge by further 
elaborating the association of each individual type of 
hormonal contraception with FSD.
Conclusion
The present study found a high prevalence of FSD in the 
study population. The most common methods of contraception 
were the use of male and female condoms and natural 
methods followed by the use of oral contraceptives and 
implants. We noted a strong association of FSD with the use 
of hormonal contraception. Other factors were found to have 
close to significant association with FSD, but this study 
was not adequately powered to show this association. These 
factors included self-employment and unemployment, use of 
alcohol within and in excess of the recommended limits and 
a history of miscarriages; the presence of any chronic illness 
or use of any chronic medication showed less significant 
associations with FSD.
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